EU Immunisation Campaigns

The EU is actively bolstering its immunisation strategy, primarily through the European Medicines Agency (EMA) and the European Centre for Disease Prevention and Control (ECDC). The EMA recently issued crucial recommendations for the 2026/2027 seasonal flu vaccine composition, ensuring timely public health protection. Concurrently, the ECDC highlights progress in cancer prevention, with three countries achieving the 90% Human Papillomavirus (HPV) vaccination target, reinforcing the effectiveness of long-term vaccination programs.

These efforts matter for citizens and businesses by safeguarding public health, reducing healthcare burdens, and ensuring a stable workforce. The EMA's new advisory group on vaccine confidence directly addresses hesitancy, aiming to boost public trust in science-based information and collective immunity. The ongoing European Immunization Week (EIW) 2026 further underscores the benefits of vaccination across all generations, promoting disease prevention and protecting lives throughout Europe.

Looking ahead, the EU is committed to strengthening its immunisation infrastructure, driven by scientific guidance and public engagement. The continuous refinement of vaccine recommendations by the EMA and the ECDC's focus on achieving high vaccination rates, such as for HPV, indicate a proactive approach. Addressing vaccine hesitancy remains a key priority, ensuring that European citizens have access to reliable information and maintain high vaccination coverage for resilient public health.